New laser device could catch spreading melanoma cells in real time
NCT ID NCT01776905
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new device that uses light and sound to detect melanoma cancer cells flowing in the blood, without needing a blood draw. The goal is to see if it can find these cells faster and more sensitively than current lab tests. About 75 people with melanoma will be tested, and each session takes about 90 minutes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Photoacoustic flow cytometry (PAFC) device
- What this could lead to
- If successful, this device could allow doctors to detect melanoma cells spreading in the blood much earlier than current tests, potentially improving monitoring and treatment decisions.
- What could go wrong
- This is an early-stage, small trial (75 people) testing a prototype device. It may not work as hoped, and results may not apply to all patients. The device is not yet proven or available for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2013
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Expect to consent approximately 80 subjects in order to achieve an enrollment goal of 75 subjects at this institution in three cohorts.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 to 80 years * Histological documented diagnosis of melanoma * Signed informed consent form approved by the University of Arkansas for Medical Sciences (UAMS) Institutional Review Board (IRB) * Must be able to sit still for 90 minutes Exclusion Criteria: * Active infection * Current and significant medical or surgical condition as determined by the Investigator * Diagnosis or evidence of organic brain syndrome * Pregnancy or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Melanoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 72205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody GNR-051 tested for safety in Hard-to-Treat cancers
- Blood test could spot Melanoma's BRAF mutation
- Can a CXCR1/2 blocker boost radiation against cancer that spreads to the brain lining?
- Can a new antibody help the immune system fight Hard-to-Treat tumors?
- Can tumor DNA and immune cells reveal why some cancers resist immunotherapy?
- Can a Two-Drug immune combo shrink melanoma tumors?